$34.02
3.15% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Stock price

$32.98
+4.72 16.70% 1M
+7.48 29.33% 6M
+5.54 20.19% YTD
-0.65 1.93% 1Y
+22.99 230.13% 3Y
-1.52 4.41% 5Y
+5.43 19.71% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+1.95 6.28%
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

Key metrics

Market capitalization $6.23b
Enterprise Value $7.57b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.75
P/S ratio (TTM) P/S ratio 28.62
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,209.77%
Revenue (TTM) Revenue $217.77m
EBIT (operating result TTM) EBIT $-532.70m
Free Cash Flow (TTM) Free Cash Flow $-451.54m
Cash position $405.73m
EPS (TTM) EPS $-2.41
P/E forward negative
P/S forward 28.45
EV/Sales forward 34.55
Short interest 16.56%
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
88%
Hold
12%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
218 218
2,209% 2,209%
100%
- Direct Costs 7.49 7.49
3% 3%
3%
210 210
9,635% 9,635%
97%
- Selling and Administrative Expenses 230 230
86% 86%
106%
- Research and Development Expense 506 506
22% 22%
233%
-526 -526
2% 2%
-242%
- Depreciation and Amortization 6.29 6.29
4% 4%
3%
EBIT (Operating Income) EBIT -533 -533
2% 2%
-245%
Net Profit -439 -439
28% 28%
-202%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Positive
Seeking Alpha
21 days ago
Attruby's recent approval positions BBIO as a direct competitor to PFE's Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a superior profile in some cases relative to Vyndaqel. BBIO is now also set to receive $500 million in milestone payments related to Attruby's approval, and I expect they'll get an additional $105 mil...
Positive
Investors Business Daily
23 days ago
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Neutral
GlobeNewsWire
23 days ago
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 550
Founded 2015
Website www.bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today